{
    "nct_id": "NCT06034002",
    "official_title": "A Phase 1, Open-Label, Multicenter Study of INCA033989 in Participants With Myeloproliferative Neoplasms",
    "inclusion_criteria": "* Life expectancy > 6 months.\n* Willingness to undergo a pretreatment and regular on-study BM biopsies and aspirates (as appropriate to disease).\n* Existing documentation from a qualified local laboratory of CALR exon-9 mutation.\n* Participants with MF or ET as defined in the protocol.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Presence of any hematological malignancy other than ET, PMF, or post-ET MF.\n* Prior history of major bleeding, or thrombosis within the last 3 months prior to study enrollment.\n* Participants with laboratory values exceeding the protocol defined thresholds.\n* Has undergone any prior allogenic or autologous stem-cell transplantation or such transplantation is planned.\n* Active invasive malignancy over the previous 2 years.\n* History of clinically significant or uncontrolled cardiac disease.\n* Active HBV/HCV or known history of HIV.\n* Any prior chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy, biological therapy, endocrine therapy, targeted therapy, antibody, or hypomethylating agent used to treat the participant's disease within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment.\n* Participants undergoing treatment with G-CSF, GM-CSF, or TPO-R agonists at any time within 4 weeks before the first dose of study treatment.\n\nOther protocol-defined Inclusion/Exclusion Criteria may apply.",
    "miscellaneous_criteria": ""
}